Onco Actu du 27 septembre 2017

	2. Etiologie
No evidence for genetic link between height and testicular cancer [Institute of Cancer Research] Risk of developing testicular cancer has doubled over the last three decades in Western countries but we don’t yet know why.
	4.1 Dép., diag. & prono. - Prostate
A prostate ‘Pep Talk’ is the wrong way to get men thinking about cancer screening [HealthNewsReview] In contrast to those thoughtful recommendations, the Pep Talk website mindlessly urges men to “schedule a free screening” at a testing center, where the only medical professional they’re likely to encounter is a lab assistant with a syringe ready to draw blood.
	4.5 Dép., diag. & prono. - Colorectal
Low-Tech Outreach Methods Improve Colorectal Cancer Screening [NCI] “Existing evidence suggests no single form of colorectal cancer screening promotion will be sufficient to achieve high rates of screening; instead, clinicians, health care administrators, and policy makers must work to combine different types of effective interventions.”
	4.9 Dép., diag. & prono. - Sein
NCI-funded TMIST study compares 2-D and 3-D mammography for finding breast cancers [NCI] By taking part in TMIST, the 165,000 planned participants will provide critical information that will help researchers learn how to most effectively screen women for breast cancer and help women make informed decisions about the screening tests in the future.
	5. Traitements
Pelvis-targeting radiotherapy safe for prostate cancer patients [Cancer Research UK] Professor Paul Workman, chief executive of the ICR, said: “Radiotherapy is often seen as perhaps old-fashioned and crude compared with other cancer treatments – but nothing could be further from the truth."
	5.12.2 Immunothérapies - CAR-T
British biotech joins race to find 'living medicines' for cancer after cash injection [The Telegraph] Autolus is thought to be the most advanced drug firm in Britain working on CAR-T therapies as a standalone company. It is developing medicines to treat multiple myeloma, leukemia and lymphoma.
Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work [EndPoints] Autolus is one of a number of upstart biotechs that think better technology — like its pattern recognition tech — can make for a much better CAR-T or T cell receptor therapy personalized for each patient.
	5.3 Traitements - FDA, EMA, NICE...
EMA Warns of Major Staff Losses in HQ Relocation [RAPS] Based on the results of a survey completed by 92% of EMA's staff earlier this month, the agency says it could lose between 19% and 94% of its staff depending on which city is selected as its future host.
Update on EMA relocation preparedness [EMA] Staff survey indicates that the future of public health in Europe is at stake.
	6. Lutte contre les cancers
Devastation to Puerto Rico threatens global medicine supply [Pharmafile] Puerto Rico became a hub for the manufacture of pharmaceuticals in the late 1960s and 1970s, taking advantage of a federal tax incentive that allowed US-based manufacturers to avoid paying tax on profits. The legacy still stands today and, though the industry is dwindling, the island still produces 16 of the top 20 selling drugs for the mainland US and seven of the top 10 drugs sold globally.
Mesothelioma Awareness Day: How research is tackling the deadly legacy of asbestos [Cancer Research UK] The UK still sees around 2,700 cases of mesothelioma each year, and the problem is far from limited to this country. Survival for the disease also remains stubbornly low, with few treatment options available.
	6.10.1 Politiques (USA)
Senate panel blocks NIH from revising translational research awards [Science] It’s the latest step in a long-running tug-of-war over the direction of the Clinical and Translational Science Awards (CTSAs) program. The CTSAs were created in 2006 by then–NIH Director Elias Zerhouni as part of his larger push to turn lab findings into treatments.
	6.11 Patients
Taking part in clinical trials – Tommy’s story [Cancer Research UK] The doctor gave me two options. One was to have very complicated surgery to remove the whole of my bladder and reconstruct it from the bowel. I decided I definitely didn’t want that. The other was to join a Cancer Research UK-funded clinical trial.
	6.6 Publications
Steps towards transparency in research publishing [Nature] As research and editorial processes become increasingly open, scientists and editors need to be proactive but also alert to risks.
	6.7 DMP, Big Data & applis
The drug-maker's guide to the galaxy [Nature] How machine learning and big data are helping chemists search the vast chemical universe for better medicines.
	6.7.2 Applis
Apple, Verily and J&J Among 9 Selected for FDA Digital Health Pilot [RAPS] As part of the pilot, participants have agreed to provide access to measures they currently use to develop, test and maintain their software products, including the collection of post-market data. Participants also agreed to be available for site visits from FDA staff, and provide information about their quality management system.
FDA selects participants for new digital health software precertification pilot program [FDA] Pilot program aims to advance the development of novel digital health applications.
	6.8 Communication
You’ve heard about precision medicine. Now get ready for precision drug ads [STAT] STAT requested interviews with more than a dozen of the largest drug makers about the ad targeting tools they’re using. None agreed to talk about how they’re promoting specific products.
	6.9 Controverses
Award or Reward? Which comes first, NIH funding or research impact? [BioRxiv] Which comes first, funding or research impact? We use causal inference to determine the direction of influence in a record of 70,000 NIH-funded investigators, which was recently released. Contrary to the basic premise of many funding policies, we find that the number of citations of an investigator determine funding levels, but not the other way around.